Loading organizations...
Attralus has raised $201.0M across 3 funding rounds.
Key people at Attralus.
Attralus has raised $201.0M in total across 3 funding rounds.
Attralus is a clinical-stage biopharmaceutical company based in South San Francisco, California, that develops pan-amyloid removal therapeutics and diagnostic imaging tools to eliminate toxic amyloid deposits in patients with systemic amyloidosis. Operating with a team of fewer than 50 employees, the enterprise has secured over $140 million in total funding to advance its clinical pipeline. The company's financial backing includes a $116 million Series B round supported by institutional investors such as venBio Partners, Cormorant Asset Management, and Omega Funds. In addition to its internal development of lead therapeutic candidate AT-02, the firm executed a strategic transaction with Bayer, which acquired its investigational imaging agents AT-01 and AT-05 for cardiac amyloidosis diagnosis. Attralus was founded in 2019 by Spencer Guthrie and Dr. Jonathan Wall based on research originating from the University of Tennessee.
Attralus has raised $201.0M in total across 3 funding rounds.
Attralus's investors include Alpha Wave Ventures, 4BIO Capital, Abingworth, venBio, Bristol Myers Squibb, Logos Capital, Sarissa Capital, Surveyor Capital, Vivo Capital, Graham Walmsley, Janus Henderson Investors, Redmile Group.
Attralus is a clinical‑stage biopharmaceutical company developing *pan‑amyloid removal (PAR)* therapeutics and diagnostic imaging agents to treat systemic amyloidosis by directly binding and clearing amyloid deposits from organs and tissues; the company launched in 2019 and has raised multiple financing rounds, including Series A, Series B and follow‑on financings led by investors such as venBio, Logos Capital and Alpha Wave Ventures.[3][4][1][2]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Health Landscape
Quick Take & Future Outlook
If you’d like, I can: (a) compile a timeline of Attralus’ financings and program milestones with dates and sources, (b) summarize competitor programs in amyloidosis for comparative context, or (c) pull the names and backgrounds of founders and senior leadership from public filings. Which would you prefer next?
Key people at Attralus.
Attralus has raised $201.0M across 3 funding rounds. Most recently, it raised $56.0M Series B in February 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2024 | $56M Series B | Alpha Wave Ventures | 4BIO Capital, Abingworth, VenBio Partners, Bristol Myers Squibb, Logos Capital, Sarissa Capital, Surveyor Capital, Vivo Capital | Announced |
| Sep 1, 2021 | $120M Series B | Graham Walmsley | 4BIO Capital, Abingworth, VenBio Partners, Janus Henderson Investors, Redmile Group, Samsara BioCapital, Alex Denner, Surveyor Capital, Vivo Capital | Announced |
| Sep 1, 2020 | $25M Series A | — | 4BIO Capital, Abingworth, VenBio Partners | Announced |